Synchronyx says refill data misses most early medication adherence risk

By AI, Created 4:50 PM UTC, May 18, 2026, /AGP/ – Synchronyx published new real-world evidence at the 2026 Pharmacy Quality Alliance Annual Meeting in Baltimore showing that 72% of nonadherence events happen in the first 30 days of therapy, with a median first missed dose at day 12.5. The findings suggest that refill-based monitoring can miss the highest-risk window and the reasons patients actually stop taking medication.

Why it matters: - Refill-based measures like PDC and MPR can show whether a prescription was filled, but not whether a dose was actually taken. - Synchronyx says that creates a blind spot during the first month of therapy, when adherence risk is highest and interventions are most likely to matter. - The findings are especially relevant for specialty pharmacies, pharma patient support programs and health systems that track adherence quality.

What happened: - Synchronyx published new real-world evidence at the 2026 Pharmacy Quality Alliance Annual Meeting in Baltimore. - The analysis found that 72% of medication nonadherence events occurred within the first 30 days of treatment. - The median first missed dose was day 12.5. - The study is titled “Beyond the Pill Count: Real-Time Dose-Level Monitoring to Identify Demographic Disparities in Medication Adherence Barriers.” - The dataset covered three years of dose-level data from 277 patients. - The cohort included oncology, inflammatory bowel disease, infectious disease and chronic conditions.

The details: - The Tappt Health platform uses battery-free NFC smart labels on medication packaging to capture dose-level behavior. - When a patient misses a dose, the platform prompts for the reason at the moment of the miss. - Synchronyx says 48% of missed doses in the cohort generated a patient-reported barrier at the point of miss. - Forgetfulness accounted for 36.9% of missed doses. - Side effects accounted for 13.8% of missed doses. - Medication concerns accounted for 4.8% of missed doses. - Provider direction accounted for 13.2% of missed doses. - Refill and supply failures accounted for 6.6% of missed doses. - PDC calculations count physician-ordered dose holds as adherence failures, which can overstate nonadherence.

Between the lines: - The study suggests different adherence problems need different responses. - Reminder-based support fits forgetfulness, but it does not address side effects, medication concerns or access barriers. - Real-time, patient-reported data can separate those causes before a care team chooses an intervention. - The analysis also points to equity gaps that aggregate refill data can hide. - White patients averaged 94% adherence, while Black patients averaged 81%. - Medicare patients averaged 93% adherence, compared with 80% for Medicaid patients. - Medication concerns were reported 11 times more often by Black patients than by White patients. - Those disparities align with the PQA Health Equity Technical Expert Panel’s focus on stratifying adherence measures by race, ethnicity and social determinants of health.

What’s next: - Synchronyx says the findings matter for branded companion programs, specialty pharmacies and other teams managing complex therapy populations. - The company is positioning real-time dose-level monitoring as a way to identify barriers while they are still actionable. - This was Synchronyx’s second straight presentation at the PQA Annual Meeting. - In 2025, the company’s SMART Reach study on real-time adherence monitoring for CDK4/6 inhibitor therapy in breast cancer received the PQA Gold Medal. - Synchronyx says the Tappt Health platform is built to give pharma manufacturers, specialty pharmacies, health systems and clinical trial sponsors real-time visibility between prescription and outcome.

The bottom line: - Synchronyx’s core claim is blunt: refill data misses the window when most adherence problems begin, and it misses why they happen.